News and Trends 20 Dec 2019 CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA …could be circumvented by delivering simple mRNA blueprints for antibody drugs into the patient, and turning the patient’s own cells into antibody factories. There are challenges to overcome on the… December 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2024 Top biotech deals of October 2024 …by small molecules developer Galecto for an undisclosed amount. Biotech deals by approach in October 2024 Antibody-drug conjugates: an R&D favorite In the world of antibody-drug conjugates (ADCs), South Korean… November 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2025 Top biotech deals in September 2025 …company Genmab’s $8 billion acquisition of Netherlands-based Merus. The latter, being a bispecific antibody developer itself, adds to Genmab’s antibody pipeline. This includes Merus’ lead asset petosemtamab for head and… October 8, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Mar 2025 Top biotech deals of February 2025 …$2.15 billion in milestone payments, with Novartis having paid $925 million upfront. Anthos will hand over its monoclonal antibody program, which is in the clinic to prevent stroke and systemic… March 6, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Can this new Antibody-Drug Conjugate Collaboration make it to the Top? Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs)… October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2022 Clinical trial of treatment for advanced solid tumors approved …non-small cell lung cancer and small cell lung cancer. Drebuxelimab is a humanized monoclonal antibody self-developed by the company with a unique mechanism to activate B-cells to generate immune responses… October 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Jan 2025 Top 19 most-performing biotech stocks of 2024 …of MNPR-101-Lu, a novel radiopharmaceutical treating aggressive solid tumors. This is the candidate Monopar decided to prioritize after Validive’s mitigated results. This compound combines MNPR-101, a humanized monoclonal antibody that… January 27, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Positive results from Eisai and Biogen Alzheimer’s trial …antibody. It met the primary endpoint and all key secondary endpoints with highly statistically significant results. Lecanemab is an investigational humanized monoclonal antibody for AD that is the result of… September 29, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2017 Hopes are up: A Second Phase III Trial for Alzheimer’s Disease …aggregates of misfolded Aβ peptides represent one of the hallmarks of Alzheimer’s pathology. Crenezumab is a fully humanized IgG4 monoclonal antibody that binds different forms of Aβ, but shows higher… February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Apr 2025 21 UK biotech companies you should know about …Inflammatory diseases Lead technology: Anti-IL-18 monoclonal antibody Recent news: Signed a license agreement for Sunshine Lake Pharma’s dual receptor agonist Apollo Therapeutics’ approach to drug development is to take breakthroughs… April 24, 2025 - 27 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2018 Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a… October 31, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic… January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email